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Introduction 
In December 2019, a new coronavirus was 
detected in Wuhan, China, named SARS-CoV-2, which 
soon spread across the world, being classified as a 
pandemic in January 2020 by the World Health 
Organization (WHO) [1-4]. 
Usually, the infection caused by SARS-CoV-2 
attacks the upper and lower respiratory tract [5], and 
may lead to a severe acute respiratory syndrome (SARS) 
[1,3,6]. As of August 2021, there were213,813,516 
confirmed cases and 4,461,982 deaths around the 
world. Brazil is one of the most important epicenters of 
COVID-19 disease, reaching 20,614,866 confirmed 
cases and 575,742 deaths [7]. The São Paulo state was 
one of the most affected locations, due to its higher 
population density, presenting 4,253,516 confirmed 
cases and 145,522 deaths [8]. Currently, the largest 
mortality rates caused by SARS-CoV-2 are associated 
with elderly people, and the presence of comorbidities 
and deficiencies of the immune system [9]. 
The COVID-19 virus spreads among humans 
through contact with oro-nasal secretions [10,11], such 
as droplets of saliva or discharge from the nose during 
cough and sneeze [12].  Due to its rapid spread it is 
indispensable the use of simple control measures to 
contain the pandemic, as the use of masks, disinfection 
of hands with soap/alcohol 70%, social distance, and 
vaccination. SARS-CoV-2 transmission usually occurs up 
seven days from the first symptoms are detected 
[13,14], while the estimated incubation period is from 
five days to two weeks, with the possibility of 
transmission by asymptomatic individuals [15,16]. 
The wide diversity of socioeconomic, climatic and 
geographic characteristics of Brazil is critical to define 
the profile of the most vulnerable population. So far, no 
studies have demonstrated the correlation between the 
epidemiological history and the main symptoms 
diagnosed individuals. Therefore, here we have choosen 
the Southeast region of Brazil, which presents the 
greatest number of COVID-19 cases, and showed the 
correlation between epidemiological features and 
symptoms.  
Therefore, this study aimed to investigate the main 
epidemiological variables associated with death in a 
population individuals notified with severe acute 
respiratory syndrome (SARS) in the capital cities of 
states from of the Southeast region of Brazil from 2020 
to 2021. Moreover, the study intends to describe, the 
correlate symptomatology, the association between 
chronic disease and COVID-19, as well as the presence 




As this is a retrospective study, analyzing 
secondary data obtained from public data sources 
(SIVEP influenza – Influenza Epidemiological 
Surveillance Information System), available at: 
https://opendatasus.saude.gov.br/dataset, this study 
did not require an evaluation by the Research Ethics 
Committee, according to the Resolution 466/2012 - 
CNS/MS. 
The epidemiology of SARS infection was described 
from patients reported in the capitals of the 
Southeastern Brazil, from May 2020 to May 2021, 
through review of the SARS notification forms of the 
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spreadsheet system, with all fields of the notification 
form from the Health System. 
The eligibility criteria were established included 
samples from individuals notified for COVID-19 disease, 
with positive RT-qPCR, presenting more than 15 years 
old, and exhibiting the outcome of the disease as cure 
or death. Individuals who did not perform the RT-qPCR 
laboratory test or presented incomplete forms were 
excluded from the analyses. 
 
Statistical Analysis 
The data were filtered and the statistical analyses 
were performed using SPSS Statistics statistical software 
v. 27.0. The significance level adopted was 5%. 
 
Results and Discussion 
The SARS-CoV-2 pandemic led the Epidemiological 
Surveillance System to make changes in the way of 
notifying respiratory diseases in early 2020, including 
COVID-19 disease. The SIVEP influenza database is 
used by the epidemiological surveillance of state and 
municipal authorities to insert the records of SARS cases 
and it is available at 
https://opendatasus.saude.gov.br/dataset/bd-srag-
2021. 
From May 2020 and May 2021, SIVEP generated a 
spreadsheet composed by 1,645,989 reported cases for 
COVID-19 in Brazil. In this study, filters were applied in 
order to follow the eligibility criteria. After refinement of 
the initial table, the number of samples included in this 
study were 90,904 (Figure 1). 
 




This epidemiological background allowed us to 
study aspects of the notified adolescent-adult 
population per each state from Southeastern Brazil. The 
evaluated variables were sex, main symptoms, 
comorbidities, and disease outcome (death or cure). 
Here, we showed that the largest number of cases were 
notified in the capital of São Paulo stated, about 61% 
cases, which can be associated with the fact of São 
Paulo city to be the biggest metropolis in the country.  
The predominance of infected males 55% over females 
is similar to other countries [17]. The most prevalent 
symptoms, such as dyspnea 79.2%, cough 79% and 
change in the oxygen saturation 75.1% present in the 
notifications were correlated with the criteria for case 
determination of SARS by the epidemiological 
surveillance.  
Besides, among the comorbidities analyzed, the 
heart disease was displayed in 40,4% of the cases, 
which can be related with hypertension or venous 
thrombosis. We showed that the lethality was observed 
in 30.6% of the analyzed cases, which could be 
associated with several factors, such as high virulence 
of the disease, comorbidities, absence of vaccination 
during the study period, among others (Table 1). 
 
Table 1. Distribution of demographic characteristics in 
the general population presenting severe acute 
respiratory syndrome due to COVID-19, from 2020 to 
2021, from Southeastern Brazil. 
 
Variables % N 
Southeast region   
Espírito Santo - ES 1.2 1,131 
Belo Horizonte - BH 12.7 11,591 
Sao Paulo-SP 61.0 55,473 
Rio de Janeiro - RJ 25.0 22,709 
   
Sex   
Masculine 55.0 50,059 
Feminine 45.0 40,834 
   
Symptoms   
Fever 70.9 53,754 
Cough 79.0 61,479 
Dyspnea 79.2 61,420 
O2* Saturation < 95% 75.1 55,236 
   
Comorbidities   
Diabetes 27.1 24,612 
Heart disease 40.4 36,751 
Obesity 7.4 6758 
   
Outcome   
Cure 68.5 58,097 
Death 30.6 26,026 
*O2 - Oxygen 
 
As this is a descriptive study, which uses secondary 
data analysis, the option "ignored” present in most fields 
of the notification form, and that was ticked several 
times in the answers, could have influenced the results 
of this study. This fact can be explained due to the high 
demand for cases to be notified by the institutions, 
reduction of qualified human resources in fill in the 
forms, or subjectivity of the investigated form item. 
However, it is worth noting that this occurrence did not 
harm the statistical analysis, due to the expressive 
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number evaluated data.  
In the period of the study, the vaccine for COVID-
19 was in testing phase, therefore these results can 
provide an overview prior to the preventive intervention. 
Studies of this magnitude can encourage further 
research that cover more regions of the country in order 
to better develop national databases, as well as public 
policies in the Health Services. 
 
Conclusion 
Comorbidities are risk factors that may be 
associated with hospitalization for COVID-19. Although 
COVID-19 has a wide spectrum of symptoms, its 
aggravation implies in several measures when referring 
to the management of human and financial resources, 
dimensioning of equipment and hospital beds, both in 
private and public medicine. Our study can be used as a 
starting point for future comparisons in different regions 
of Brazil and other countries. The data obtained here 
can provide important clues for future understanding of 
prevention and control of COVID-19 in individuals 
around the world.  
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